NEW HAVEN, Conn., February 6, 2023 (GLOBE NEWSWIRE) — Arvinas, Inc. ARVNa clinical-stage biotechnology company developing a new class of drugs based on targeted protein degradation, today announced that management will attend three upcoming investor conferences:

• Guggenheim Oncology Conference on Thursday February 9th. Ron Peck, MD, Chief Medical Officer, and Sean Cassidy, Chief Financial Officer, will participate in a fireside chat. A live audio webcast of the presentation will be available Here and in the Events + Presentations section of the Company’s website.
• SVB Leerink Global Health Conference on Thursday February 16th. Ron Peck, MD, Chief Medical Officer, and Randy Teel, Ph.D., Senior Vice President, Corporate and Business Development will participate in a fireside chat. A live audio webcast of the presentation will be available Here and in the Events + Presentations section of the Company’s website.
• Citi Oncology Leadership Summit on Thursday February 23rd. Ian Taylor, Ph.D., Chief Scientific Officer, will participate in a fireside chat. A live audio webcast of the presentation will be available Here and in the Events + Presentations section of the Company’s website.
  

About Arvinas
Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients with debilitating and life-threatening diseases by discovering, developing and commercializing therapies that break down disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to develop proteolysis-targeted chimeras, or PROTAC®-directed protein degraders, that are designed to leverage the body’s natural protein disposal system to selectively and efficiently degrade disease-causing proteins and to remove. In addition to its robust preclinical pipeline of PROTAC® protein digesters against validated and “non-drug” targets, the Company has three clinical-stage investigational programs: bavdegalutamide (ARV-110) and…